Atossa Therapeutics Announces Third Quarter 2024 ... - Morningstar

4 days ago · G&A professional fees and other expense increased by $0.3 million and $1.9 million for the three and nine months ended September 30, 2024, respectively, compared to the prior …

CouponFollow Extension

$0
OFF

Atossa Therapeutics Announces Third Quarter 2024 ... - Morningstar

1 week from now

4 days ago · G&A professional fees and other expense increased by $0.3 million and $1.9 million for the three and nine months ended September 30, 2024, respectively, compared to the prior …

morningstar.com

$0
OFF

Atossa Therapeutics Announces Third Quarter 2024 Financial …

1 week from now

4 days ago · G&A professional fees and other expense increased by $0.3 million and $1.9 million for the three and nine months ended September 30, 2024, respectively, compared to the prior …

einnews.com

$0
OFF

Atossa Therapeutics Announces Third Quarter 2024 Financial …

1 week from now

4 days ago · The decrease in G&A compensation expense of $0.2 million and $2.5 million for the three and nine months ended September 30, 2024, respectively, compared to the prior year …

marketscreener.com

$2417304
OFF

The Healthcare Foundation Of NJ Announces $2,417,304 In Third …

1 week from now

Sep 18, 2024 · The Healthcare Foundation of NJ (HFNJ) is pleased to announce that it has awarded $2,417,304 to eighteen nonprofit organizations in its third quarterly grant cycle of …

hfnj.org

3%
OFF

TherapeuticsMD Announces Third Quarter 2024 Financial Results

1 week from now

4 days ago · Total operating expenses for the third quarter of 2024 were $1.4 million, a decrease of $314 thousand, or 18.3%, compared to $1.7 million for the third quarter of 2023.

morningstar.com

$3
OFF

Chemomab Therapeutics Announces Third Quarter 2024

1 week from now

2 days ago · Net Loss: Net loss was $3.5 million, or a net loss of approximately $0.01 per basic and diluted ordinary share for the third quarter of 2024, compared to $4.1 million, or a net loss …

morningstar.com

$11
OFF

Protara Therapeutics Announces Third Quarter 2024 ... - Morningstar

1 week from now

4 days ago · For the third quarter of 2024, Protara incurred a net loss of $11.2 million, or $0.50 per share, compared with a net loss of $9.9 million, or $0.87 per share, for the same period in …

morningstar.com

FAQs about Atossa Therapeutics Announces Third Quarter 2024 ... - Morningstar Coupon?

What happened to Atossa Therapeutics?

SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended March 31, 2024, and provid... ...

What did Atossa Therapeutics announce in its third-quarter financial report for 2024?

In their third-quarter financial report for 2024, Atossa Therapeutics announced several significant achievements, including positive results from their KARISMA-Endoxifen Phase 2 study and promising preliminary data from other clinical trials. ...

Is Atossa Therapeutics (Atos) a good stock to buy?

ATOS is trading within a range we consider fairly valued. Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. ...

Does Atossa support Breast Cancer Awareness Month?

SEATTLE, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), today announced its recognition and support of Breast Cancer Awareness Month this Octob... ...